Overview

Prostatilen is a peptide bioregulator derived from the prostate glands of young bulls, belonging to the class of cytomedins — tissue-specific peptide complexes developed by the Khavinson school of bioregulatory medicine at the Saint Petersburg Institute of Bioregulation and Gerontology. The preparation contains a mixture of low-molecular-weight peptides (typically 1-10 kDa) that are proposed to exhibit organotropic specificity for prostatic tissue, meaning they preferentially accumulate in and exert biological effects on the prostate gland. Prostatilen has been used clinically in Russia and several CIS countries since the 1990s as a rectal suppository or intramuscular injection for the treatment of chronic prostatitis and benign prostatic hyperplasia (BPH).

The proposed mechanism of action involves multiple pathways relevant to prostatic pathology. Prostatilen reduces inflammation within the prostate by suppressing pro-inflammatory cytokine production, decreasing neutrophil infiltration, and modulating local immune responses. It also improves microcirculation within the prostate gland, reducing edema and congestion that contribute to lower urinary tract symptoms. Additionally, prostatilen has been reported to normalize prostatic secretory function, restore antimicrobial properties of prostatic fluid, and improve sperm quality parameters — effects attributed to the bioregulatory peptides' ability to restore physiological gene expression patterns in prostatic epithelial cells. Clinical studies conducted primarily in Russian medical institutions have reported improvements in symptom scores, reduction in prostate volume, normalization of prostatic secretion markers, and enhanced quality of life.

Prostatilen is not approved by the FDA or EMA and remains largely unknown outside of Russian and Eastern European medical practice. The scientific evidence base, while extensive in Russian-language literature, has limited representation in Western peer-reviewed journals. A zinc-enriched formulation (Prostatilen-Zinc) combines the peptide complex with zinc and vitamin E for enhanced prostatic support. The bioregulatory peptide concept shares philosophical ground with other tissue-derived peptide therapies including thymalin and epithalon, also developed within the Khavinson research program. Western counterparts for prostate health include saw palmetto, beta-sitosterol, and pharmaceutical 5-alpha reductase inhibitors.

Mechanism of Action

Mechanism of Action: Prostatilen

Prostatilen is a complex of cytomedin peptides isolated from bovine prostate glands, functioning as a bioregulatory agent with organotropic specificity for prostatic tissue.

Anti-inflammatory Activity

The peptide complex downregulates NF-κB signaling in prostatic tissue, reducing production of TNF-α, IL-1β, and IL-6. This decreases leukocyte infiltration, edema, and tissue damage associated with chronic prostatitis and benign prostatic hyperplasia (BPH). Prostatilen also reduces cyclooxygenase-2 (COX-2) expression, limiting prostaglandin-mediated inflammation.

Microvascular Effects

Prostatilen improves prostatic microcirculation by inhibiting platelet aggregation and enhancing nitric oxide (NO)-dependent vasodilation in small prostatic vessels. This improved blood supply reverses tissue ischemia, a key contributor to BPH progression and chronic pelvic pain.

Smooth Muscle and Urodynamic Effects

By modulating alpha-1 adrenergic receptor density and sensitivity in prostatic and bladder neck smooth muscle, prostatilen reduces urethral resistance and improves detrusor contractility. This leads to improved urinary flow rates and reduced post-void residual volume.

Immunomodulatory Properties

Prostatilen enhances local mucosal immunity through increased secretory IgA levels and activation of tissue macrophages. This strengthens the prostate's defense against bacterial infection, which is particularly relevant in chronic bacterial prostatitis (NIH category II).

Trophic Effects

The peptide complex promotes normalization of prostatic epithelial cell proliferation and secretory function, potentially mediated through growth factor modulation including epidermal growth factor (EGF) and transforming growth factor-beta (TGF-β) pathways.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Prostatilen

Common Side Effects

• Injection or suppository site irritation: pain, burning, and local inflammation
• Mild allergic reactions: pruritus, urticaria, and rash
• Transient worsening of urinary symptoms during initial treatment
• Mild headache and dizziness

Serious Adverse Effects

• Anaphylactic reactions (rare, due to bovine prostate extract origin)
• Potential for prion disease transmission theoretically, as it is derived from bovine prostate tissue (no confirmed cases)
• Rare cardiovascular effects: mild hypotension
• Coagulation changes due to zinc component in some formulations

Contraindications

• Known allergy to bovine-derived products
• Active prostate cancer or suspected prostate malignancy (may mask symptoms)
• Severe cardiovascular disease
• Children and women (prostate-specific product)

Drug Interactions

• Anticoagulants: Zinc component may affect platelet function
• Alpha-blockers: Additive effects on urinary symptoms; generally beneficial but monitor for hypotension
• 5-alpha reductase inhibitors: Often used concurrently; no significant adverse interactions known

Population-Specific Considerations

• Primarily available in Russia/CIS countries: Limited Western regulatory oversight; quality assurance varies
• BPH patients: Primary indication; used as rectal suppositories or IM injections
• Elderly men: Most common user population; well tolerated in clinical studies from Eastern European literature
• Not FDA-approved: No standardized Western manufacturing or quality requirements

Pharmacokinetic Profile